Bergenfield, NJ, United States of America

Kenneth A Jones

This inventor holds 13 USPTO granted patents, primarily in Neuropeptide Receptor Biology. Top assignees: H. Lundbeck A/s, Synaptic Pharmaceutical Corporation. Active years: 2001-2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kenneth A Jones. Retrieved from https://idiyas.com/inventor/kenneth-a-jones

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 53.8

Average Co-Inventor Count = 4.3

ph-index = 3

Forward Citations = 19(Granted Patents)


Location History:

  • Bergenfield, NJ (US) (2001 - 2007)
  • Belmont, MA (US) (2006 - 2008)
  • Glen Rock, NJ (US) (2009)

Company Filing History:


Years Active: 2001-2009

Loading Chart...
Areas of Expertise:
SNORF33 Receptor
NPFF Receptor
Galanin Receptor
Chimeric G Proteins
Agonists
Antagonists
DNA Encoding
Cell Expression
Receptor Interactions
Pharmaceutical Applications
Neuropeptides
Biological Compositions
13 patents (USPTO):Explore Patents

Title: Innovations of Kenneth A. Jones

Introduction

Kenneth A. Jones is a notable inventor based in Bergenfield, NJ (US), recognized for his significant contributions to the field of biotechnology. He holds a total of 13 patents, showcasing his innovative spirit and dedication to advancing scientific knowledge.

Latest Patents

Among his latest patents are methods for preparing compositions using a SNORF33 receptor. This invention encompasses isolated nucleic acids encoding mammalian SNORF33 receptors, purified mammalian SNORF33 receptors, and vectors comprising nucleic acid encoding these receptors. Additionally, it includes cells that contain such vectors, antibodies directed to mammalian SNORF33 receptors, and nucleic acid probes useful for detecting nucleic acids encoding these receptors. The patent also covers antisense oligonucleotides complementary to unique sequences of nucleic acids encoding mammalian SNORF33 receptors, as well as transgenic, nonhuman animals that express DNA encoding normal or mutant mammalian SNORF33 receptors. Furthermore, it outlines methods for isolating mammalian SNORF33 receptors, treating abnormalities linked to their activity, and determining the binding of compounds to these receptors. The invention also identifies agonists and antagonists of SNORF33 receptors.

Another significant patent involves processes for determining compounds that interact with the SNORF33 receptor. This patent shares many similarities with the previous one, providing a comprehensive approach to understanding and utilizing the SNORF33 receptor in various applications.

Career Highlights

Kenneth has worked with prominent companies in the pharmaceutical and biotechnology sectors, including H. Lundbeck A/S and Synaptic Pharmaceutical Corporation. His experience in these organizations has contributed to his expertise and innovative capabilities in the field.

Collaborations

Throughout his career, Kenneth has collaborated with notable professionals, including Beth E. Borowsky and Christophe P. G. Gerald. These collaborations have likely enriched his work and expanded the impact of his inventions.

Conclusion

Kenneth A. Jones is a distinguished inventor whose work on SNORF33 receptors has the potential to advance therapeutic approaches in biotechnology. His numerous patents reflect his commitment to innovation and the betterment of scientific understanding.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…